Iovance To Press Ahead With Melanoma Cell Therapy Filing Despite Doubters

Still Expects To File In 2022

 
• By Andrew McConaghie
  
Iovance
Iovance is no stranger to share price turbulence, but looks well placed to file its potential first-in-class cell therapy in August. • Source: Shutterstock

More from Business

More from Scrip